Evofem Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $865.23K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 18, 2026 | Before market open | $900.00K | $-0.04 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | After market close | $9.60M | $0.00 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $5.00M | $-0.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $4.80M | $-0.02 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 1, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 28, 2023 | Before market open | – | – | – |
Press releases
Announcements Evofem Biosciences filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fifth Consecutive Year of Net Sales Growth
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Financial Results for Third Quarter of 2025, Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Announces Voting Results from Special Meeting of Stockholders
Agreement terminated · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Middle East with Pharma 1
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
the Third Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
the Second Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
Signs Phexxi ® License Agreement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Divests U.S. Commercial Women’s Health Specialty Business to Evofem, including SOLOSEC
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Financial Results for the First Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports $18.2 million of Phexxi Net Product Sales in 2023
Results of operations · EX-99.1 to Form 8-K
Evofem Biosciences Announces Strong Preliminary
Results of operations · EX-99.1 to Form 8-K
Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi ® , the First and Only FDA-Approved
Material agreement · Agreement terminated · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Financial Results for the
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Preliminary Results for the Third Quarter of 2023
Results of operations · EX-99.1 to Form 8-K
Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Financial Results for the Second Quarter of 2023
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Financial Results for the First Quarter of 2023
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces 1-for-125 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K